使用 Light Adjustable Lens™ 先体验再确定您的视力

正在阅读这篇文章的您很可能正在考虑使用 Light Adjustable Lens (LAL™),这是一种用于白内障手术的新型晶状体植入体,可让您掌控自己的视力。使用 Light Adjustable Lens,您可以亲自提前体验手术后的视力,并根据自己的生活方式进行微调,以确保达到最佳效果。

手术后,您可以先体验新的视力,然后医生会根据您的生活方式和视力需求来调整晶状体度数参数配置。在晶状体度数永久锁定之前,此过程最多可重复三次。在您开始这段疗程时,请使用本博客作为指南,来了解定制视力的过程。

遵循您的眼药水疗程

手术后,您的眼科护理团队可能会开不同类型的眼药水处方(如下所述),以帮助眼睛恢复并减轻炎症。为了达到最佳效果,请务必仔细遵照医嘱。

  • 处方眼药水:这类眼药水有助于预防感染并帮助度过恢复过程。医生会为您的眼睛提供具体的治疗方案,请务必遵照医生的指导。
  • 人工泪液:可能会建议使用这类人工泪液,以保持眼睛的水分和舒适度。您的眼科医疗服务提供者将为您提供建议。

在日常生活情境中测试您的视力

在进行日常活动时,请注意双眼的视力表现。避免比较双眼的视力,因为双眼本应协调工作。以下是一些有用的提示:

  • 家和工作场所评估您的视力。尝试阅读书籍或屏幕上的文本。
  • 在您喜爱的活动和爱好中测试您的视力。尝试阅读棋盘游戏的规则,观看带字幕的电影,以及观察光线和距离对视力的影响。
  • 写日记记录您的视力体验
  • 记下任何变化或疑虑,以便与您的眼科护理团队讨论。

获得清晰的视力不是一朝一夕的事。可能需要几次就诊来微调效果。请记住,您的新晶状体与您的天然晶状体不同,所以请给眼睛一些时间来适应。

您的视力,由您掌控。

定制您的视力是一个合作的过程,需要您与医生保持联系,在光照治疗之间监测您的视力,并遵照您的处方眼药水方案。遵循这些步骤将有助于确保您的眼睛正常愈合,达到最佳视力效果。优化体验的关键包括以下几点:

  • 观察您的视力在不同情况下(家庭、工作、业余爱好等)的反应。
  • 跟踪您的视力进展情况,并与您的眼科护理专业人士交流任何疑虑。
  • 保持耐心。获得最佳视力需要时间,但这项投资将为您带来更清晰、个性化的终身视力。

如需了解有关 Light Adjustable Lens 的更多信息,请访问我们的常见问题页面。如果您想与专业人士交流,在我们的网站上查找医生

近期文章

白内障手术与干眼症:须知事项

固定型与可调节型晶状体设计:了解哪种设计更适合您

了解白内障手术:让您的视力从此更清晰

LAL patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

The Light Adjustable Lens provides optimized vision for patient satisfaction.2

Light Adjustable Lens patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

Since the Light Adjustable Lens is a monofocal lens, there is low risk of dysphotopsias caused by splitting light, leading to potentially enhanced vision and patient satisfaction.

LAL patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The Light Adjustable Lens offers LASIK-like accuracy in cataract surgery.2,3

92% of eyes (N = 391) achieved results within 0.50 D of target manifest refraction spherical equivalent (MRSE).

Patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The study was a prospective, controlled, multicenter, 12-month study of 600 patients (ITT population) randomized to receive implantation with the RxSight LAL (N = 403) or a commercially available monofocal IOL (N = 197). Effectiveness analyses included 391 LAL patients and 193 control patients. Primary safety variables included best spectacle-corrected visual acuity (BSCVA) at 6 months and incidence of sight-threatening complications and adverse events. Primary effectiveness variables included percent reduction in manifest cylinder at 6 months, percent mean absolute reduction in MRSE at 6 months, and rotation of meridian of LAL at 6 months. Percent of eyes with an uncorrected visual acuity (UCVA) of 20/20 or better at six months post-operatively compared between the LAL treatment group and the monofocal control group was a secondary endpoint.

The Light Adjustable Lens corrects as low as 0.50 D of astigmatism, which is the lowest level approved to be treated.

The ability to treat 0.50 D of postoperative cylinder makes the Light Adjustable Lens the only IOL in the United States approved to correct this level of vision-altering astigmatism. Astigmatism of as little as 0.50 D can reduce visual acuity by one line, and the impact on dynamic, functional visual acuity and low-contrast acuity is even greater.1